Atezolizumab vs Durvalumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Atezolizumab

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02008227 · Phase 3 · completed

This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.

Next expected readout: November 2026 · NCT04958811 (registry estimate)

Reported efficacy

Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) (Up to approximately 96 months): IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 (missed)

Result source: NCT03456063

Durvalumab

Marketed by AstraZeneca and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02125461 · Phase 3 · completed

Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251).

Next expected readout: December 2026 · NCT05000710 (registry estimate)

Reported efficacy

Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.): Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) (met)

Result source: NCT02125461

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAtezolizumabDurvalumab
PFS, median7 vs 5.5vs Nab-Paclitaxel+Carboplatinn 456NCT02367781
40 other results
16.8 vs 5.6+11.2 vs placebon 476NCT02125461
24 other results
OS, median13.8 vs 9.6vs Docetaxeln 425NCT02008227
36 other results
11.7 vs 8.7vs SoCn 62NCT02352948
20 other results
ORR11% vs 10.5%vs Atezolizumab IV1875 mg · n 245NCT03735121
30 other results
60.7% vs 60.6%+0.1 vs placebon 219NCT03519971
10 other results
  • 35.5% vs 6.8% n 62 · Phase 3 · secondary NCT02352948
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 15.4% vs 6.8% n 117 · Phase 3 · secondary NCT02352948
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 35% vs 23.9% wk 16 · n 60 · Phase 2 · primary NCT03822351
  • 40.3% vs 23.9% wk 16 · n 62 · Phase 2 · primary NCT03822351
  • 58.1% n 62 · Phase 2 · secondary NCT02572843
Duration of response, median16.3 vs 6.2vs Docetaxeln 58NCT02008227
33 other results
30.7 vs 18.6+12.1 vs placebon 133NCT03519971
17 other results

PFS, median

Atezolizumab
7 vs 5.5vs Nab-Paclitaxel+Carboplatinn 456NCT02367781
40 other results
Durvalumab
16.8 vs 5.6+11.2 vs placebon 476NCT02125461
24 other results

OS, median

Atezolizumab
13.8 vs 9.6vs Docetaxeln 425NCT02008227
36 other results
Durvalumab
11.7 vs 8.7vs SoCn 62NCT02352948
20 other results

ORR

Atezolizumab
11% vs 10.5%vs Atezolizumab IV1875 mg · n 245NCT03735121
30 other results
Durvalumab
60.7% vs 60.6%+0.1 vs placebon 219NCT03519971
10 other results
  • 35.5% vs 6.8% n 62 · Phase 3 · secondary NCT02352948
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 15.4% vs 6.8% n 117 · Phase 3 · secondary NCT02352948
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 35% vs 23.9% wk 16 · n 60 · Phase 2 · primary NCT03822351
  • 40.3% vs 23.9% wk 16 · n 62 · Phase 2 · primary NCT03822351
  • 58.1% n 62 · Phase 2 · secondary NCT02572843

Duration of response, median

Atezolizumab
16.3 vs 6.2vs Docetaxeln 58NCT02008227
33 other results
Durvalumab
30.7 vs 18.6+12.1 vs placebon 133NCT03519971
17 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety

Coverage. Atezolizumab: 17 of 17 rows · Durvalumab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAtezolizumab
Rows use multiple source trials
Durvalumab
Rows use multiple source trials
Disease Control
responder rate · % of participants
100% (n=1) vs 50% (n=4) Atezolizumaba,b,c
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
65.8% (n=219) vs 65.1% (n=109) placebo @ 24wka,b,c
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
2 other source trials
80% (n=60) vs 58.2% (n=67) Durvalumab Monotherapy
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
79% (n=62) vs 58.2% (n=67) Durvalumab Monotherapy
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
16.6 monthsd,e,f,g,c
NCT03285763 · Phase 4 · registry result, not featured evidence
show 1 more dose
20.5 months
NCT03285763 · Phase 4 · registry result, not featured evidence
12.3 monthse,f,g,c
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
7 other source trials
13.13 months*
NCT04249362 · Phase 2 · registry result, not featured evidence · converted to months from 56.9 weeks as posted
7.87 months*
NCT04249362 · Phase 2 · registry result, not featured evidence · converted to months from 34.1 weeks as posted
NA months
NCT03693300 · Phase 2 · registry result, not featured evidence
9.95 months*
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 43.1 weeks as posted
9.95 months*
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 43.1 weeks as posted
5.79 months*
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 25.1 weeks as posted
5.79 months*
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 25.1 weeks as posted
Major Pathologic
responder rate · % of participants
No placebo or comparator arm
65.4% (n=26) @ 12wk*f,h
NCT02716038 · Phase 2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
11.1% (n=27) @ 6wk1500 mgd,f,h
NCT03794544 · Phase 2 · registry result, not featured evidence
show 3 more doses
31.3% (n=16) @ 6wk1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
30% (n=20) @ 6wk1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
19% (n=21) @ 6wk1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
11.5% (n=615)d,e,f,g,c
NCT03285763 · Phase 4 · registry result, not featured evidence
show 1 more dose
12.4% (n=615)
NCT03285763 · Phase 4 · registry result, not featured evidence
58.1% (n=62)e,f,g,c
NCT02572843 · Phase 2 · registry result, not featured evidence
OS Rate at 12
responder rate · % of participants
45.49% (n=107) vs 24.79% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) @ 104wkf,g
NCT02409342 · Phase 3
58.4% (n=219) vs 59.5% (n=109) placebo @ 104wkf,g
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival
time to event · months
No placebo or comparator arm
11.2 monthsi,f,c
NCT03285763 · Phase 4 · registry result, not featured evidence
9 other source trials
17.5 months
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
12.6 months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
14.2 months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
14.06 months
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03102242 · Phase 2 · registry result, not featured evidence
14.82 months
NCT02848651 · Phase 2 · registry result, not featured evidence
14.4 months
NCT01846416 · Phase 2 · registry result, not featured evidence
6.8 months
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
9.3 months
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
10 monthsd,i,f,c
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more dose
11.5 months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival Rate at 12
absolute value · percentage points
No placebo or comparator arm
86.8% (n=38) @ 52wkf,g
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
64% (n=53) @ 52wkd,f,g
NCT04249362 · Phase 2 · registry result, not featured evidence
show 1 more dose
65.5% (n=49) @ 52wk
NCT04249362 · Phase 2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
2.7 monthsd,i,f,c
NCT03285763 · Phase 4 · registry result, not featured evidence
show 1 more dose
3.7 months
NCT03285763 · Phase 4 · registry result, not featured evidence
3.1 monthsd,i,f,c
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more dose
3.5 months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS-12
absolute value · months
No placebo or comparator arm
4.64 months @ 52wkf,g
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
6.83 months @ 52wk*f,g
NCT04003246 · Phase 2 · registry result, not featured evidence · converted to months from 208 days as posted
PFS12
absolute value · percentage points
No placebo or comparator arm
68.4% (n=38) @ 52wkf,g
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
46.8% (n=53) @ 52wkd,f,g
NCT04249362 · Phase 2 · registry result, not featured evidence
show 1 more dose
31.8% (n=49) @ 52wk
NCT04249362 · Phase 2 · registry result, not featured evidence
Progressive Disease
event count · % of participants
No placebo or comparator arm
progressive disease (PD)
7.9% (n=38)*f,g,c
progressive disease (PD)
NCT04776447 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
26% (n=38)f,g,c
Progressive Disease (PD)
NCT02879617 · Phase 2 · registry result, not featured evidence
Stable Disease
event count · % of participants
No placebo or comparator arm
Stable disease (SD)
18.4% (n=38)*f,g,c
Stable disease (SD)
NCT04776447 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
47% (n=38)f,g,c
Stable Disease (SD)
NCT02879617 · Phase 2 · registry result, not featured evidence
Time to Response
time to event · months
No placebo or comparator arm
1.577 monthsf,c
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
2.1 monthsd,f,c
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
1.9 months
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestonej
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT02409342 · Phase 3
n/a: no completion milestone
NCT02367781 · Phase 3 · combination
97.9%
NCT03285763 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
100%1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
38.5%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
66.7%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
53.3%1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03191786 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
15.8%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
5.6%
NCT04042558 · Phase 2 · registry result, not featured evidence
—Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
—Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
36.5%
NCT02927301 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
16.1%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
3.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
0%
NCT03526900 · Phase 2 · registry result, not featured evidence
69.3%
NCT02848651 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT01903993 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneAtezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneRandomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneSafety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
62.6%k
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
79%Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
75.2%Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.1%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
76.3%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
31%
NCT04416633 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
100%
NCT04642469 · Phase 3 · registry result, not featured evidence
26.7%
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
—Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
0%Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
0%Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
90%
NCT04003246 · Phase 2 · registry result, not featured evidence
1.5%
NCT02572843 · Phase 2 · registry result, not featured evidence
51.7%Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
51.6%Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
66.7%Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
13.3%Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
13.3%Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02879617 · Phase 2 · registry result, not featured evidence
3.7%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
6.3%1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
14.3%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
78.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
91.2%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
7.1%Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
0%Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—j
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT02409342 · Phase 3
—
NCT02367781 · Phase 3 · combination
—
NCT03285763 · Phase 4 · registry result, not featured evidence
—
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
—
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
—1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—
NCT03191786 · Phase 3 · registry result, not featured evidence
—
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
0.6%Arm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
—
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
—
NCT04042558 · Phase 2 · registry result, not featured evidence
—Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
—Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
0%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
—
NCT02927301 · Phase 2 · registry result, not featured evidence
—
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
—
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
3.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
—
NCT03526900 · Phase 2 · registry result, not featured evidence
—
NCT02848651 · Phase 2 · registry result, not featured evidence
—Cohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
—Cohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
—Cohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
—
NCT01903993 · Phase 2 · registry result, not featured evidence
9.7%Atezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Randomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—Safety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—k
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
—Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6%
NCT04416633 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT04642469 · Phase 3 · registry result, not featured evidence
—
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
—Cohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
—Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
—Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
—Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
—
NCT04003246 · Phase 2 · registry result, not featured evidence
—
NCT02572843 · Phase 2 · registry result, not featured evidence
—Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
—Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
—Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
—Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
—
NCT02879617 · Phase 2 · registry result, not featured evidence
—1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
—1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
—1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
—1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
4.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
11.8%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
—Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
—Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Serious AEs
32.8%j
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
42.5%Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
48.3%Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
33.9%
NCT02409342 · Phase 3
53.3%
NCT02367781 · Phase 3 · combination
32.2%
NCT03285763 · Phase 4 · registry result, not featured evidence
32.9%
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
41.1%
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
20.2%1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
15.4%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
20.5%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
26.7%1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
49%
NCT03191786 · Phase 3 · registry result, not featured evidence
51.2%
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
45.5%Arm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
50.3%Arm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
55.1%
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
55.3%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
48.5%
NCT04042558 · Phase 2 · registry result, not featured evidence
13.5%Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
8.4%Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
100%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
34.8%
NCT02927301 · Phase 2 · registry result, not featured evidence
17.4%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
10%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
53.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
17.5%
NCT03526900 · Phase 2 · registry result, not featured evidence
53.3%
NCT02848651 · Phase 2 · registry result, not featured evidence
34.1%Cohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
43.5%Cohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
44.8%Cohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
37.3%
NCT01903993 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
54.8%Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
46.2%Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
49.5%Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
47.7%Randomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
57.1%Safety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
29.1%k
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
37.1%Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
30.8%Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
37.6%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
47%
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
44.2%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
21%
NCT04416633 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
7.1%
NCT04642469 · Phase 3 · registry result, not featured evidence
31.1%
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
16.2%Cohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
35.3%Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
43.4%Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
36.7%Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
70%
NCT04003246 · Phase 2 · registry result, not featured evidence
53.7%
NCT02572843 · Phase 2 · registry result, not featured evidence
—Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
27.9%Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
33.9%Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
28.1%Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
0%Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
40%Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
50%Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
55.3%
NCT02879617 · Phase 2 · registry result, not featured evidence
11.5%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
31.3%1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
9.5%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
60.9%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
46.2%Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
41.7%Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
j
fatigue 27.1%
decreased appetite 24.6%
cough 24%
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 36 more results
alopecia 45%
anaemia 36.5%
nausea 32.5%
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 47.8%
nausea 37.9%
fatigue 34.9%
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 17.5%
decreased appetite 17.5%
fatigue 15.4%
NCT02409342 · Phase 3
anaemia 54.8%
nausea 49.9%
fatigue 48.2%
NCT02367781 · Phase 3 · combination
cough 17.4%
decreased appetite 16.9%
fatigue 16.3%
NCT03285763 · Phase 4 · registry result, not featured evidence
pruritus 22.6%
rash 20.9%
cough 19.7%
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 44.9%
decreased appetite 31.9%
nausea 25.4%
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
1875 mg
anaemia 19%
cough 13.4%
decreased appetite 12.6%
NCT03735121 · Phase 3 · registry result, not featured evidence
1800 mg
asthenia 38.5%
cough 38.5%
diarrhoea 30.8%
NCT03735121 · Phase 3 · registry result, not featured evidence
1800 mg
anaemia 33.3%
fatigue 28.2%
nausea 23.1%
NCT03735121 · Phase 3 · registry result, not featured evidence
1200 mg
anaemia 33.3%
asthenia 20%
blood cholesterol increased 20%
NCT03735121 · Phase 3 · registry result, not featured evidence
decreased appetite 22%
cough 19.7%
fatigue 19.3%
NCT03191786 · Phase 3 · registry result, not featured evidence
anaemia 44.3%
nausea 38.5%
constipation 31.6%
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
anaemia 39.5%
alopecia 39.2%
fatigue 29.2%
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
anaemia 56.3%
nausea 39.2%
neutropenia 36.2%
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
anaemia 52.8%
nausea 39.7%
constipation 33.3%
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
neutrophil count decreased 26.3%
anemia 15.8%
febrile neutropenia 13.2%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
asthenia 77.9%
nausea 75%
anaemia 64.7%
NCT04042558 · Phase 2 · registry result, not featured evidence
pruritus 9%
arthralgia 7.9%
cough 7.9%
NCT05171777 · Phase 2 · registry result, not featured evidence
injection site reaction 10.3%
diarrhoea 6.5%
asthenia 5.2%
NCT05171777 · Phase 2 · registry result, not featured evidence
atrial flutter 100%
dry mouth 100%
dysplastic naevus 100%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
fatigue 43.6%
procedural pain 29.8%
dyspnoea 22.7%
NCT02927301 · Phase 2 · registry result, not featured evidence
proteinuria 30.4%
aspartate aminotransferase increased 26.1%
fatigue 26.1%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
neutropenia 50%
alanine aminotransferase increased 6.7%
aspartate aminotransferase increased 6.7%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.6%
nausea 53.1%
dyspnea 51.6%
NCT03102242 · Phase 2 · registry result, not featured evidence
fatigue 37.5%
anemia 20%
anorexia 10%
NCT03526900 · Phase 2 · registry result, not featured evidence
fatigue 44.1%
nausea 27.6%
decreased appetite 27%
NCT02848651 · Phase 2 · registry result, not featured evidence
fatigue 37.7%
cough 31.9%
dyspnoea 30.4%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 31.6%
nausea 25.7%
cough 24.5%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 36.5%
cough 32.1%
decreased appetite 29.4%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 38.7%
decreased appetite 35.9%
cough 31.7%
NCT01903993 · Phase 2 · registry result, not featured evidence
fatigue 51.6%
nausea 35.5%
constipation 25.8%
NCT01846416 · Phase 2 · registry result, not featured evidence
constipation 46.2%
fatigue 38.5%
diarrhoea 30.8%
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
fatigue 40.9%
cough 35.5%
dyspnoea 32.3%
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
cough 36.4%
asthenia 31.8%
dyspnoea 29.5%
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 71.4%
hypertension 57.1%
asthenia 42.9%
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
k
cough 35.6% (placebo 25.2%)
fatigue 24% (placebo 20.1%)
dyspnoea 22.3% (placebo 24.4%)
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 32 more results
decreased appetite 25.8%
constipation 21%
cough 17.7%
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
decreased appetite 23.1%
diarrhoea 21.4%
fatigue 18.8%
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
diarrhoea 20.8%
decreased appetite 19.7%
asthenia 17.9%
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 41.1% (placebo 37%)
neutropenia 26.9% (placebo 25.9%)
nausea 25.1% (placebo 24.1%)
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 45.5%
nausea 41.2%
neutropenia 29.7%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
cough 20%
pyrexia 19%
dyspnoea 13%
NCT04416633 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
hypothyroidism 28.6% (placebo 0%)
asthenia 21.4% (placebo 0%)
pruritus 21.4% (placebo 0%)
NCT04642469 · Phase 3 · registry result, not featured evidence
nausea 42.2% (placebo 40.9%)
anaemia 33.3% (placebo 27.3%)
fatigue 33.3% (placebo 27.3%)
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
cough 23.4%
decreased appetite 13.5%
fatigue 13.5%
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 26.8%
fatigue 26%
cough 21.1%
NCT02087423 · Phase 2 · registry result, not featured evidence
fatigue 29.4%
constipation 23.5%
cough 19.1%
NCT02087423 · Phase 2 · registry result, not featured evidence
anaemia 24.5%
asthenia 24.5%
dyspnoea 20.8%
NCT04249362 · Phase 2 · registry result, not featured evidence
cough 24.5%
constipation 20.4%
fatigue 20.4%
NCT04249362 · Phase 2 · registry result, not featured evidence
weight loss 80%
anorexia 70%
fatigue 70%
NCT04003246 · Phase 2 · registry result, not featured evidence
fatigue 68.7%
nausea 67.2%
diarrhea 62.7%
NCT02572843 · Phase 2 · registry result, not featured evidence
cough 42.6%
asthenia 24.6%
pruritus 24.6%
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
cough 32.2%
dyspnoea 25.4%
asthenia 18.6%
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
cough 37.7%
asthenia 25.4%
dyspnoea 23.7%
NCT03693300 · Phase 2 · registry result, not featured evidence
asthenia 66.7%
cough 66.7%
dyspnoea 66.7%
NCT03693300 · Phase 2 · registry result, not featured evidence
constipation 66.7%
fatigue 60%
cough 43.3%
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
constipation 70%
anemia 53.3%
fatigue 46.7%
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
anemia 63.8%
hypoalbuminemia 55.3%
lymphocyte count decreased 48.9%
NCT02879617 · Phase 2 · registry result, not featured evidence
1500 mg
fatigue 23.1%
procedural pain 19.2%
asthenia 11.5%
NCT03794544 · Phase 2 · registry result, not featured evidence
1500 mg + 200 mg
dyspnoea 18.8%
fatigue 18.8%
alanine aminotransferase increased 12.5%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
1500 mg + 750 mg
constipation 10%
fatigue 10%
pruritus 10%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
1500 mg + 3000 mg
fatigue 19%
asthenia 14.3%
cough 14.3%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 34.8%
fatigue 34.8%
anaemia 30.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
cough 35.3%
fatigue 32.4%
nausea 32.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 92.3%
cough 76.9%
dyspnea 76.9%
NCT03801902 · Phase 1 · registry result, not featured evidence
dyspnea 75%
fatigue 75%
cough 66.7%
NCT03801902 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 4.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gTreatment context has not been resolved for both arms.
  8. hAssessment timepoints differ: 6 weeks versus 12 weeks.
  9. iTrial phases differ: Phase 3 versus Phase 4.
  10. jPopulation comparability has not been reviewed for 35 of these studies.
  11. kPopulation comparability has not been reviewed for 29 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Atezolizumab

All-cause Mortality 63.8% (n=425) vs 70.1% (n=425) Docetaxel
responder rate · % of participants
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
62.7% (n=241) vs 67.1% (n=222) Docetaxel
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 8.3 vs 6.8 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
7 vs 5.6 Nab-Paclitaxel+Carboplatin months
ITT Population
NCT02367781 · Phase 3 · combination
Overall Survival 19.8 vs 14.9 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
19 vs 15 Bevacizumab+Paclitaxel+Carboplatin months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 9 vs 5.7 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
ORR 49.3% (n=347) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
responder rate · % of participants
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
63.5% (n=353) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival Rate at 12 64.9% (n=107) vs 50.64% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) @ 52wk
responder rate · % of participants
NCT02409342 · Phase 3
Time to Deterioration Cough 3.5 vs 3.4 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Cough
NCT02409342 · Phase 3
Time to Deterioration Dyspnea 1.3 vs 1 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Dyspnea
NCT02409342 · Phase 3
show 1 more result
11.1 vs 11.8 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
Dyspnea
NCT02409342 · Phase 3
Time to Deterioration Chest Pain 1.7 vs 1.1 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Chest pain
NCT02409342 · Phase 3
Time to Deterioration LC13 Cough NA vs NA Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Cough
NCT02409342 · Phase 3
show 1 more result
NA vs 21.4 Vinorelbine or Gemcitabine months
Cough
NCT03191786 · Phase 3 · registry result, not featured evidence
Time to Deterioration LC13 Chest Pain NA vs NA Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Chest pain
NCT02409342 · Phase 3
show 1 more result
NA vs NA Vinorelbine or Gemcitabine months
Chest Pain
NCT03191786 · Phase 3 · registry result, not featured evidence
Overall Survival 21.2 vs 16.9 Nab-Paclitaxel+Carboplatin months
time to event · months
TC1/2/3 or IC1/2/3 ITT Population
NCT02367781 · Phase 3 · combination

+ 817 further endpoints in the CSV export.

Durvalumab

ORR 30% (n=443) vs 17.8% (n=213) placebo
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
46.3% (n=335) vs 48.5% (n=330) D + SoC
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS12 55.9% (n=476) vs 35.3% (n=237) placebo @ 52wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS18 44.2% (n=476) vs 27% (n=237) placebo @ 78wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Death or Distant Metastasis 28.3 vs 16.2 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
51 vs 46.3 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
OS24 66.3% (n=476) vs 55.6% (n=237) placebo @ 104wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS2 28.3 vs 17.1 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
9.1 vs 6.7 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
8 vs 6.7 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
27.8 vs 22 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
10.4 vs 10.2 D + SoC months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS Rate at 6 35.5% (n=62) vs 24.1% (n=64) SoC @ 24wk
responder rate · % of participants
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 2 more results
31.5% (n=174) vs 24.1% (n=64) SoC @ 24wk
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
27.2% (n=117) vs 24.1% (n=64) SoC @ 24wk
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
APF12 19.4% (n=62) vs 9.9% (n=64) SoC @ 48wk
responder rate · % of participants
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 2 more results
20.6% (n=174) vs 9.9% (n=64) SoC @ 48wk
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
15% (n=117) vs 9.9% (n=64) SoC @ 48wk
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Complete 1.8% (n=219) vs 1.8% (n=109) placebo
responder rate · % of participants
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 Global Health Status -0.5 vs 0.2 placebo score @ 52wk
absolute change · score
EORTC QLQ-C30: Global health status/QoL
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 Physical Functioning -1.4 vs -0.8 placebo score @ 52wk
absolute change · score
EORTC QLQ-C30: Physical functioning
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 Fatigue 1.3 vs 0.3 placebo score @ 52wk
absolute change · score
EORTC QLQ-C30: Fatigue symptoms
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

+ 32 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atezolizumab's landscape · Durvalumab's landscape